Brief: Cognition Therapeutics Says Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement In Cognitive Outcomes
29/07/2024 12:17
July 29 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS’ PROOF-OF-CONCEPT PHASE 2 SHINE
TRIAL
DEMONSTRATES CONSISTENT IMPROVEMENT IN COGNITIVE OUTCOMES WITH
ONCE-DAILY ORAL CT1812 IN MILD-TO-MODERATE ALZHEIMER’S PATIENTS
* COGNITION THERAPEUTICS INC: FAVORABLE SAFETY PROFILE WITH
MOST
TREATMENT-RELATED ADVERSE EVENTS MILD OR MODERATE
* COGNITION THERAPEUTICS INC: CONSISTENT POSITIVE CHANGES
ACROSS
COGNITIVE AND FUNCTIONAL MEASURES
* COGNITION THERAPEUTICS INC: CT1812 TREATMENT SHOWED ABOUT
40%
MEAN IMPROVEMENT IN COGNITIVE MEASURES VERSUS PLACEBO
Source text for Eikon: ID:nGNX5swCqj
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB